Oral Combination Treatment of Gefitinib (IressaTM) and Sasam-Kyeongokgo: Synergistic Effects on the NCI-H520 Tumor Cell Line

The aim of this research was to confirm the possible synergic effects sasam-Kyeongokgo (SKOG) on anti-tumor activity gefitinib using athymic nude mice bearing human non-small-cell lung squamous cell carcinoma (NSCLC) NCI-H520 line after continuous oral combination treatment provided daily for 35 days within a timeframe 5 min, as developing process novel preventive and therapeutic regimes various types cancer. After days, BW, tumor volume weight, lymphatic periovarian fat pad weight measurements, well serum IFN-γ IL-6 level, NK activity, splenic cytokine content together with histopathological observations, immunohistochemistry measurements treated control mice, were performed. results suggest that co-administration SKOG 400, 200, or 100 mg/kg markedly increased through immunostimulatory also dramatically inhibited cancer cachexia effect, potentiating gefitinib, favorable anti-cachexia effects. Therefore, over can provide an effective regimen patients.